Ei Moe Phyu, MD, MBBS

Peer-Reviewed Articles

1. Simbaqueba Clavijo, CA, Odaro, OE, Gandhi, A, Koom-Dadzie, K, Musaelyan, A, Dickson, KB, Chua, R, Bhise, VR, Amoateng, MD, Tomy, S, Leal Alviarez, DJ, Phyu, EM, Bogdanich, I, Andersen, C, Sheshadri, A, Palaskas, NL, Halm, J, Manzano, JM. Immunotherapy-Related Adverse Events and Clinical Outcomes in Adult Solid-Tumor Patients Admitted to an Onco-Hospitalist Medicine Service. Cancers 17(3), 2025. e-Pub 2025. PMID: 39941771.
2. Thein KZ, Htut TW, Myat YM, Han MM, Win MA, Phyu EM, Oo TH. Updated meta-analysis of randomized controlled trials on primary outpatient thromboprophylaxis in patients with gastric and gastroesophageal junction cancers receiving chemotherapy. Baylor University Medical Center Proceedings 36(5):635-640, 2023. e-Pub 2023. PMID: 37614866.

Abstracts

1. Thein KZ, Htut TW, Han MM, Myat YM, Win MA, Phyu EM, Oo TH. Systematic Review and Meta- Analysis of Randomized Controlled Trials on Primary Outpatient Thromboprophylaxis (POTP) in Patients with Gastric and Gastro-Esophageal Junction (GEJ) Cancers Receiving Chemotherapy, 2022. e-Pub 2022.
2. Thein KZ, Htut TW, Han MM, Myat YM, Win MA, Phyu EM. Updated Meta-Analysis of Randomized Controlled Trials on Primary Outpatient Thromboprophylaxis (POTP) in Patients with Advanced Pancreatic Cancer (APC) Receiving Chemotherapy cancer, 2022. e-Pub 2022.
3. Htut T, Thein K, Win M, Phyu E, Lawrie A, Tighe J, Preston G. Efficacy of Daratumumab Combination Regimen in Patients with Multiple Myeloma: A Combined Analysis of Six Phase III Randomized Controlled Trials. British Journal of Hematology 189(Supplement 1):4-294 p 127, 2020. e-Pub 2020.
4. Htut T, Thein K, Win M, Phyu E, Lawrie A, Tighe J, Preston G. Risk of Pneumonia and Tolerability in Patients with Multiple Myeloma Treated with Daratumumab: A Systematic Review and Combined Meta- analysis of Six Phase III Randomized Controlled Trials. British Journal of Hematology 189(Supplement 1):4-294 p118, 2020. e-Pub 2020.
5. Htut T, Thein K, Awasthi S, Sultan A, Swarup S, Win M, Phyu |, Dash A, Han M, Myat Y, Hardwicke F, Tijani L, D’Cunha N, Quick D. Daratumumab-related Hematological Toxicities in Patients with Multiple Myeloma: A Combined Analysis of Five Phase III Randomized Controlled Trials Blood134(Supplement 1):3485-3485, 2019. e-Pub 2019.
6. Htut T, Tun A, Sultan A, Win M, Swarup S, Phyu E, Hlaing P, Han M, Myat Y, Hardwicke F, Quick D, D’Cunha N, Tijani L, Thein K. Updated Meta-analysis of Randomized Controlled Trials to Evaluate the Incidence of Infection and Pneumonia in Patients with Multiple Myeloma Treated with Daratumumab Blood1234(Supplement 1):4771-4771, 2019. e-Pub 2019.
7. Htut T, Quick D, Win M, Swarup S, Sultan A, Ball S, Phyu E, Yu N, Han M, Myat Y, Hardwicke F, D’Cunha N, Awasthi S, Thein K. Incidence of Second Primary Malignancies and Peripheral Sensory Neuropathy in Patients with Multiple Myeloma Receiving Daratumumab Containing Regimen Blood134(Supplement 1):5550-5550, 2019. e-Pub 2019.
8. Htut T, Win M, Swarup S, Sultan A, Adhikari N, Phyu E, Dash A, Han M, Myat Y, Awasthi S, Tijani L, D’Cunha N, Quick D, Thein K. Tolerability in Patients with Multiple Myeloma Treated with Daratumumab: A Systematic Review and Meta-analysis of Phase III Randomized Controlled Trials Blood134(Supplement 1):1873-1873, 2019. e-Pub 2019.
9. Thein K, Htut T, Win M, Swarup S, Sultan A, Ball S, Phyu E, Tun A, Pandey R, Han M, Hardwicke F, Tijani L, D’Cunha N, Quick D. Efficacy of Upfront Daratumumab Combination Regimen in Patients with Newly Diagnosed Multiple Myeloma Blood134(Supplement 1):3158-3158, 2019. e-Pub 2019.
10. Sultan A, Grant B, Quick D, Graf C, Swarup S, Kopel J, Htut T, Ball S, Phyu E, Han M, Myat Y, D’Cunha N, Win M, Thein K. Efficacy of Phosphatidylinositol 3-kinase (PI3K) Inhibitors in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Blood134(Supplement 1):5480, 2019. e-Pub 2019.
11. Grant B, Sultan A, D’Cunha N, Graf C, Swarup S, Win M, Phyu E, Htut T, Han M, Myat Y, Adhikari N, Yu N, Quick D, Thein K. Phosphatidylinositol 3-kinse (PI3K) Inhibitors-related Hematological Toxicities in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Blood134(Supplement 1):5877-5877, 2019. e-Pub 2019.
12. Swarup S, Quick D, Sultan A, Win M, Phyu E, Htut T, Wongsaengsak S, Zin M, Aung Y, Han M, Myat Y, Awasthi S, Tijani L, Thein K. Incidence of Serious Adverse Events, Pneumonitis, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Treated with Phosphatidylinositol 3-kinase (PI3K) Inhibitors Blood134(Supplement 1):798-798, 2019. e-Pub 2019.
13. Kopel J, Swarup S, Sultan A, Tijani L, Phyu |, Win M, Htut T, Aung Y, Dash A, Han M, Myat Y, Quick D, D’Cunha N, Thein K. Risk of Serious Adverse Events, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Treated with Idelalisib Blood134(Supplement 1):5489-5489, 2019. e-Pub 2019.
14. Win MA, Thein KZ, Phyu EM, Han MM, Quick D, Cortorreal P, Tijani L, Griffin E. Risk of gastrointestinal toxicities and health-related quality of life events in patients with multiple myeloma treated with daratumumab 18(1):S241-S242, 2018. e-Pub 2018.
15. Win MA, Thein KZ, Phyu EM, Han MM, D’Cunha P, Joseph Nelson III, Quick D, Sklar A. Daratumumab-related pulmonary toxicities in patients with multiple myeloma: a systematic review and meta-analysis of phase III randomized controlled trials 18(1):S242, 2018. e-Pub 2018.
16. Phyu EM, Thein KZ, Win MA, Tijani L, Quick D, Cortorreal P, D’Cunha N. Risk of health-related quality of life events from fatigue, anorexia, pyrexia, electrolyte imbalance and dermatological toxicities in patients with chronic lymphocytic leukemia treated with idelalisib. Journal of National Comprehensive Cancer Center Network 16:e-1-e-55, 2018. e-Pub 2018.
17. Thein KZ, Phyu EM, Win MA, D’Cunha N, Quick D, Pendergrast K, Tijani L. A systematic review and meta-analysis of randomized controlled trials to evaluate the risk of pulmonary toxicities in patients with chronic lymphocytic leukemia treated with idelalisib. Journal of National Comprehensive Cancer Center Network 16:e-1-e-55, 2018. e-Pub 2018.
18. Thein KZ, Win MA, Phyu |M, D’Cunha N, Currie M, Tijani L, Quick D. Risk of gastrointestinal and hepatic toxicities in patients with chronic lymphocytic leukemia treated with idelalisib: A systematic review and meta-analysis of randomized controlled trials. Journal of National Comprehensive Cancer Center Network 16:e-1-e-55, 2018. e-Pub 2018.
19. Win MA, Thein KZ, Phyu . A systematic review and meta- analysis of randomized controlled trials to evaluate the risk of hematological toxicities in patients with multiple myeloma treated with daratumumab 18(1):S242-243, 2018. e-Pub 2018.